Trial Profile
Randomized study of oral ganciclovir versus i.v. ganciclovir for preemptive therapy of cytomegalovirus infection after stem cell transplantation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary) ; Ganciclovir
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 12 Oct 2022 Status changed from recruiting to completed (Date of the global end of the trial 29 May 2018)
- 24 Apr 2012 New trial record